Table 1.
Phenotypic consequence of EGFR downregulation by siRNAs
| Name of siRNA | exon | sequence | Locationa | Designed by | RNA knockdown Measured with q2 (%) | Protein downregulation (%) | Viability (%) | Caspase-3/7 (%) | Apoptotic cells (%) | Viable cells (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| EGFR siRNA604 | 3 | GCAGTCTTATCTAACTATGATGCAA | C.604_628 | Invitrogen | 19 ± 5 | 43 ± 3 | 94 ± 2 | 170 ± 8 | 168 ± 6 | 90 ± 2 |
| EGFR siRNA752 | 4 | GCAGTGACTTTCTCAGCAA | C.752_770 | Eurogentec | 44 ± 13 | 28 ± 1 | 96 ± 2 | 149 ± 6 | 137 ± 6 | 94 ± 1 |
| EGFR siRNA1247 | 8-9 | GCAAAGTGTGTAACGGAATAGGTAT | C.1247_1271 | Invitrogen | 72 ± 4 | 51 ± 3 | 92 ± 0 | 179 ± 6 | 177 ± 7 | 86 ± 2 |
| EGFR siRNA1608 | 12 | GGAGATAAGTGATGGAGAT | C.1608_1626 | Eurogentec | 25 ± 9 | 11 ± 1 | 97 ± 2 | 132 ± 7 | 131 ± 6 | 94 ± 1 |
| EGFR siRNA2654 | 20 | GGGAACACAAAGACAATAT | C.2654_2672 | Dharmacon | 18 ± 22 | 1 ± 1 | 106 ± 1 | 102 ± 6 | 104 ± 2 | 92 ± 1 |
| EGFR siRNA2708 | 20-21 | TCGCAAAGGGCATGAACTA | C.2708_2726 | Dharmacon | 21 ± 9 | 8 ± 1 | 106 ± 1 | 141 ± 6 | 136 ± 6 | 105 ± 2 |
| EGFR siRNA3768 | 28 | GGACTTCTTTCCCAAGGAA | C.3768_3786 | Eurogentec | 48 ± 8 | 2 ± 1 | 97 ± 2 | 126 ± 6 | 125 ± 6 | 96 ± 1 |
| EGFR siRNA4765 | 28 | AGAATGTGGAATACCTAAGG | C.4766_4785 | * | 2 ± 7 | 2 ± 1 | 108 ± 3 | 146 ± 6 | 137 ± 6 | 93 ± 3 |
| Negative siRNA | proprietary sequence designed by Eurogentec | 16 ± 11 | 3 ± 1 | 111 ± 2 | 97 ± 2 | 100 ± 2 | 97 ± 0 | |||
| Blank control | 1 ± 5 | 1 ± 0 | 116 ± 2 | 107 ± 4 | 101 ± 1 | 98 ± 1 |
aReference sequence identical to NM_005228.3 b Modified from [7].